Yasheng’s AI-Powered Cancer Therapy Patent Revolutionizes Immunotherapy Development

San Jose, California, Feb. 24, 2023 (GLOBE NEWSWIRE) — Yasheng’s AI-Powered Cancer Therapy Patent Revolutionizes Immunotherapy Development

SAN JOSE, CA–(February 24, 2023) – Yasheng Group, (OTC: HERB), an agricultural and biotech company with U.S. headquarters in San Jose, California today announced that HERB filed for patent protection with the USPTO. The invention relates to the use of artificial intelligence (AI) to improve cancer immunotherapy. The provisionally patented technology aims to use AI in various aspects of immunotherapy development, including antigen characterizations, AI-based immune signatures, prediction of immunotherapy responses, manufacturing optimization, and AI assistance in clinical trials. AI can assist in identifying antigens and binding sites for CAR T-cell therapies, characterizing the tumor-immune microenvironment, and predicting immunotherapy responses. It can also optimize the manufacturing process of CAR-T and CAR-NK cell therapies, reducing time and costs and improving clinical success rates. The invention’s unique features include the use of AI in multiple aspects of immunotherapy development, which has the potential to improve diagnostic accuracy, optimize treatment planning, predict outcomes of care, and reduce human resource costs.

Yasheng Group

Yasheng Group (“The Company”) is a Colorado corporation that conducts business operations in US, China, and the Philippines in four major segments: Agriculture, Mining, Biotechnology, and Blockchain + IoT. The company’s agriculture products include herbal medicine, herbal organic food, ginkgo, solarium, betel nut, coconut, coffee, wolfberry, and hemp. Its products are exported to 15 countries around the world and 2875 Cooperative regional distribution agents. It also designs, develops, and markets new technologies related to agriculture and genetic biology.

Safe Harbor Statement

Except for the historical information contained herein, certain matters discussed in this press release are forward-looking statements that involve risks and uncertainties such as expectations of future growth and profits. The company assumes no obligation to update these forward-looking statements.

CONTACT: Yasheng Group 
2245 Fortune Dr # C,
San Jose, CA 95131
15108604685
info@yashenggroup.com

Staff

Recent Posts

Predictmedix AI Announces Closing of Final Tranche of Non-Brokered Private Placement

Toronto, Ontario--(Newsfile Corp. - December 5, 2025) - Predictmedix AI Inc. (CSE: PMED) (OTC Pink:…

36 minutes ago

Techficient Launches Surefire, Its Proprietary Modern Underwriting Engine

BOISE, Idaho, Dec. 5, 2025 /PRNewswire/ -- Techficient, a leading innovator in Insurtech solutions, announces the…

36 minutes ago

Clinical Education Alliance Becomes Decera Clinical, Delivering Education, Insights, and Communications

Company brings its Scientific Activation™ mission to life at ASH Annual Meeting following November rebrand RESTON,…

36 minutes ago

Shrub Oak International School Reinforces Unwavering Commitment to Student Safety and Security

MOHEGAN LAKE, N.Y., Dec. 5, 2025 /PRNewswire/ -- Shrub Oak International School today announced enhanced…

36 minutes ago

‘I’D RATHER GET A ROOT CANAL’: US WORKERS DREAD THE OFFICE HOLIDAY PARTY

National poll reveals 27% of workers prefer dental work over office celebrations as workplace disconnection…

36 minutes ago

Medicus Pharma Ltd. Enters Into $5.1 Million Warrant Inducement

Maxim Group LLC is acting as the exclusive Financial Advisor for the transaction PHILADELPHIA, PA…

36 minutes ago